Announcing a new symposium on prostate cancer being held at the 11th European Multidisciplinary Congress on Urological Cancers

Medthority.com is excited to announce an upcoming symposium to be held at EMUC19, the 11th European Multidisciplinary Congress on Urological Cancers.

“ARE YOU TESTING? DNA REPAIR ALTERATIONS IN PROSTATE CANCER CARE AND CASCADE TESTING IN FAMILY MEMBERS” will focus on the molecular heterogeneity of prostate cancer, particularly DNA damage repair gene mutations (for example, in BRCA2 and ATM), and its impact on clinical practice.

Speaking on behalf of Medthority.com, Dr Cornelia Meisenberg said:

“We’re thrilled to be bringing together a high profile faculty to help drive the conversation forward in advanced prostate cancer. A better understanding of the role for DNA repair gene alterations in prostate cancer care and the practical and clinical considerations for molecular testing can help us to embrace what looks like an imminent paradigm shift in treatment and patient management”. 

The symposium will be presented by a leading faculty from prostate cancer and DNA repair fields. It will be chaired by Dr Neal Shore and feature presentations from Professor Johann de Bono, and Dr Alex Wyatt.

The symposium will take place on Saturday 16 November at 17.45–18.45 in Hall F2 of the Austria Center, Vienna, and aims to look specifically at metastatic castrate-resistant prostate cancer (mCRPC) patients who do not respond to standard therapies.

Dr Meisenberg continued:

“There is increasing evidence that DNA repair gene mutations in prostate cancer may serve as a marker for personal and family risk of cancer, and also as prognostic and predictive markers. We hope this symposium will encourage HCP confidence in embracing this complicated topic that is likely to impact on clinical practice in the near future”.

“ARE YOU TESTING? DNA REPAIR ALTERATIONS IN PROSTATE CANCER CARE AND CASCADE TESTING IN FAMILY MEMBERS”
Date: Saturday 16th November 2019
Time: 17:45 – 18:45
Venue: Hall F2, Austria Centre Vienna

Chair: Dr Neal Shore Medical Director for the Carolina Urologic Research Centre, USA

Faculty

• Professor Johann de Bono Director of Drug Development Unit and Head of Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust
• Dr Alex Wyatt Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia

Agenda

• 17.45–17.50 Welcome and introductions – Dr Neal Shore
• 17.50–18.00 Patient diagnosis and mCRPC – Dr Neal Shore
• 18.00–18.15 Clinical impact of DNA damage repair alterations in prostate cancer – Professor Johann de Bono
• 18.15–18.30 Molecular diagnostics for testing DNA damage repair alterations – Dr Alex Wyatt
• 18.30–18.45 Faculty discussion and meeting close – Dr Neal Shore

This symposium is sponsored by AstraZeneca, and is restricted to Healthcare Professionals only

About the project
Delivered through an educational grant from AstraZeneca this project will deliver a symposium at one of the leading European oncology congresses, to address unmet needs in advanced prostate cancer. 

About Medthority.com
Medthority.com, the website for healthcare professionals, aims to bring together healthcare professionals from around the world through the submission of real-world case studies. 

About EMUC Vienna, Austria - 14 Nov - 17 Nov 2019
EMUC19 brings together specialists and healthcare professionals from various disciplines, including oncologists, urologists, radiotherapists, and pathologists. It includes collaborative input from several societies: the European Society for Medical Oncology (ESMO), the European Society for Radiotherapy & Oncology (ESTRO) and the European Association of Urology (EAU). 
The congress aims to encourage discussions on innovative treatment, the limits of standard therapies, and the impact of new research outcomes, to help identify optimal therapies and address gaps in clinical practices.